Bexxar (iodine I 131 tositumomab)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Bexxar |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | 2 |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20 found on the surface of a variety of B-cells, including lymphoma cells, and some myeloma cells. The radioactive iodine attached to the antibody delivers radiation directly to these cells which works to harm or kill the cancer cells. Approximately 20-25% of patients with multiple myeloma have this protein on the surface of their tumor cells.
Clinical Trials:
For a list of clinical trials studying Bexxar for the treatment of multiple myeloma, see ClinicalTrials.gov.
See also the official Bexxar website.
Updated August 27, 2008.
Related Articles:
- Getting To Know: TNB-383B
- Getting To Know: Tiragolumab
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Lather, Rinse, Repeat: Will It Work With BCMA-Targeted Therapies For Multiple Myeloma?
